Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maze Therapeutics (MAZE) FCF Margin (2024 - 2026)

Maze Therapeutics' FCF Margin history spans 2 years, with the latest figure at 195.6% for Q1 2026.

  • On a quarterly basis, FCF Margin changed N/A to 195.6% in Q1 2026 year-over-year; TTM through Mar 2026 was 606.24%, a N/A change, with the full-year FY2024 number at 498.71%, changed N/A from a year prior.
  • FCF Margin hit 195.6% in Q1 2026 for Maze Therapeutics, down from 15.12% in the prior quarter.
  • Over the last five years, FCF Margin for MAZE hit a ceiling of 96.44% in Q2 2024 and a floor of 932.32% in Q3 2024.